|
Delayed
TEL AVIV STOCK EXCHANGE
09:50:31 2026-10-20 EDT
|
5-day change | 1st Jan Change | ||
| 1,466.00 ILa | +2.66% |
|
-4.50% | -9.39% |
| 09-08 | InterCure Regains Nasdaq Compliance | MT |
| 08-24 | InterCure Ltd. announced that it has received ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors. | CI |
Company Valuation: InterCure Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 440.5 | 932.3 | 550.5 | 211 | 271.8 | 176.9 |
| Change | - | 111.63% | -40.95% | -61.66% | 28.77% | -34.89% |
| Enterprise Value (EV) 1 | 407.6 | 844.6 | 572.9 | 305.4 | 404.5 | 313.3 |
| Change | - | 107.2% | -32.17% | -46.69% | 32.45% | -22.55% |
| P/E | -11.2x | 207x | 12.2x | -3.41x | -4.01x | -4.87x |
| PBR | 1.6x | 2.09x | 1.1x | 0.46x | 0.71x | 0.45x |
| PEG | - | -2x | 0x | 0x | -0.45x | 0.1x |
| Capitalization / Revenue | 6.77x | 4.24x | 1.42x | 0.59x | 1.14x | 0.65x |
| EV / Revenue | 6.27x | 3.84x | 1.47x | 0.86x | 1.69x | 1.16x |
| EV / EBITDA | 286x | 23.8x | 11.9x | 45.7x | -5.17x | -5.66x |
| EV / EBIT | -338x | 27.8x | 14x | -203x | -4.6x | -4.66x |
| EV / FCF | -33x | 116x | -12.3x | -5.23x | -13x | -8.37x |
| FCF Yield | -3.03% | 0.86% | -8.16% | -19.1% | -7.71% | -11.9% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -7.33 | 0.5 | 4.941 | -6.8 | -7.4 | -3.322 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 65.04 | 219.7 | 388.7 | 355.6 | 238.8 | 270.2 |
| EBITDA 1 | 1.425 | 35.53 | 48.34 | 6.681 | -78.22 | -55.34 |
| EBIT 1 | -1.205 | 30.41 | 40.85 | -1.503 | -87.89 | -67.24 |
| Net income 1 | -37.23 | 4.692 | 44.82 | -61.96 | -67.8 | -35.71 |
| Net Debt 1 | -32.88 | -87.64 | 22.37 | 94.35 | 132.8 | 136.3 |
| Reference price 2 | 81.76 | 103.60 | 60.40 | 23.16 | 29.69 | 16.18 |
| Nbr of stocks (in thousands) | 5,388 | 8,999 | 9,115 | 9,115 | 9,153 | 10,936 |
| Announcement Date | 3/31/21 | 4/5/22 | 3/31/23 | 5/1/24 | 5/1/25 | 4/30/26 |
1ILS in Million2ILS
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 54.55M | |
| 13.48x | 0.41x | 8.53x | 2.87% | 119B | |
| 15.36x | 1.89x | 9.44x | 0.68% | 98.48B | |
| -282.1x | 19.42x | -331.64x | -.--% | 57.57B | |
| 13.41x | 1.5x | 9.05x | 2.6% | 28.37B | |
| 23.1x | 2.58x | 13.1x | 1.41% | 25.93B | |
| 22.88x | 2.1x | 12.05x | 0.91% | 25.86B | |
| 8.09x | 1.45x | 6.57x | -.--% | 21.45B | |
| 29.98x | 5.46x | 22.67x | 2.32% | 20.45B | |
| 20.05x | 1.8x | 9.03x | 3.54% | 18.69B | |
| Average | -15.08x | 4.07x | -26.80x | 1.59% | 41.54B | |
| Weighted average by Cap. | -25.04x | 4.07x | -37.25x | 1.58% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- INCR Stock
- Valuation InterCure Ltd.
Select your edition
All financial news and data tailored to specific country editions
